Evaluation of local immune response after intravesical bacille Calmette-Guérin treatment for superficial bladder cancer

British Journal of Urology

Volumn 78, Issue 5, 1996, Pages 709-714

  Patard, J J ^a,b   Muscatelli Groux, B ^a   Saint, F ^a   Popov, Z ^a   Maille, P ^a   Abbou, C ^a   Chopin, D ^a  

^a Centre de Recherches Chirurgicales   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

Antigens; Bladder neoplasms; Cytokines; Mycobacterium bovis

Indexed keywords

BCG VACCINE; GAMMA INTERFERON;

ANTIGEN EXPRESSION; ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOLOGY; LYMPHOCYTIC INFILTRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; SUPERFICIAL CANCER;

ANTIGENS, NEOPLASM; BCG VACCINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; MAJOR HISTOCOMPATIBILITY COMPLEX; T-LYMPHOCYTE SUBSETS; URINARY BLADDER NEOPLASMS;

EID: 0030404606     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1996.01928.x     Document Type: Article

References (41)

1. Mathé G, Amiel J, Schwarzenberg L et al. Acute immunotherapy for acute lymphoblastic leukemia. Lancet 1969; 1: 697-9
2. Grant RM, Cochran AJ, Hoyle D, Mackie R, Murray EL, Ross C. Results of administering BCG to patients with melanoma. Lancet 1974; 9: 1096-110
3. Morales A, Eidinger D. Bacillus Calmette-Guerin in the treatment of adenocarcinoma of the kidney. J Urol 1976: 115: 377-80
4. Zbar B, Bernstein ID, Rapp HJ. Suppression of tumor growth at the site of injection with living bacillus Calmette-Guerin. J Natl Cancer Inst 1971; 46: 831-9
5. Morales A. Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180-3
6. Lamm DL. Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol 1985; 134: 40-7
7. Herr HW, Pinsky CM. Whitmore WF, Sogani PC. Oettgen HF. Melamed MR. Experience with intravesical bacillus Calmette-Guerin therapy of superficial bladder tumors. Urology 1985; 25: 119-23
8. Herr HW. Laudone VP, Badalament RA et al. Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988; 6: 1450-5
9. Lamm DL. Blumenstein BA. Crawford ED et al. A randomized trial of intravesical Doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 1991; 325: 1205-9
10. Brossman SA. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 1982: 128: 27-9
11. Rintala E. Jauhiainen K, Alfthan O et al. Intravesical chemotherapy (Mitomycin C) versus Immunotherapy (Bacillus Calmette-Guerin) in superficial bladder cancer. Eur Urol 1991; 20: 19-25
12. Trinchieri G. Perussia B. Immune Interferon: a pleiotropic lymphotoxin with multiple effects. Immunology Today 1985; 6: 131-6
13. Basham TY, Merigan TC. Recombinant Interferon gamma increases HLA-DR synthesis and expression. J Immunol 1983; 130: 1492-5
14. Ozello L. Habif DV. De Rosa CM, Cantel K. Cellular events accompanying regression of skin recurrences of breast carcinomas treated with intralesional injection of natural interferons a and y. Cancer Res 1992: 52: 4571-81
15. Tran R, Horan Hand P. Greiner JW, Petska S, Schlom J. Enhancement of surface antigen expression on human breast carcinoma cells by recombinant human interferons. J Interferon Res 1988; 8: 75-8
16. Hawkyard S. Jackson AM. James K, Prescott AM, Smyth JF, Chisholm GD. The inhibitory effects of interferon gamma on the growth of bladder cancer cells. J Urol 1992; 147: 1399-1403
17. Novick D, Engelmann H, Wallach D, Leitner O, Revel M, Rubinstein M. Purification of soluble cytokine receptors from normal human urine by ligand-affinity and immunoaffinity chromatography. J Chromat 1990; 510: 331-7
18. Fradet Y. Cordon-Cardo C. Thomson T et al. Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc Natl Acad Sci USA 1984: 81: 224-8
19. Bergeron A, LaRue H, Fradet Y. Identification of a superficial bladder tumor asociated glycoform of the carcinoembryonic antigen by monoclonal antibody 19A211. Cancer Res 1996: 56: 908-15
20. Chopin DK, DeKernion JB, Rosenthal DL, Fahey JL. Monoclonal antibodies against transitional cell carcinoma for detection of malignant urothelial cells in bladder washing. J Urol 1985; 134: 260-5
21. Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JH. Radioimmunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 1990; 144: 1248-51
22. De Boer EC, De Jong WE, Steerenberg PA et al Induction of urinary interleukin-1 (IL-1), IL2, IL6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer. Cancer Immunol Immunother 1992; 34: 306-12
23. Bohle A, Nowc CH, Ulmer AJ et al. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J Urol 1990; 144: 59-63
24. Thalmann GN, Dewald B, Gallati H, Baggiolini M, Studer UE. Interleukin-8 (IL 8), Interleukin 6 (IL 6), Tumor necrosis factor a (TNF a), soluble TNF receptors (sTNFR) 75kDa and 55 kDa after BCG therapy of urothelial cancer (TCC): cytokine kinetics over 6 instillations. Urol Res 1993; 21: 468
25. Ratliff TL, Haaf EO, Catalona WJ. Interleukin-2 production during intravesical Bacille Calmette-Guerin therapy for bladder cancer. Clin Immunonol Immunopathol 1986; 40: 375-9
26. Fleischmann JD, Toosi Z, Ellner JJ, Wentworth DB, Imbembo AL. Urinary interleukins in patients receiving intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. Cancer 1989; 64: 1447-54
27. De Boer EC, Schamhart DHJ, De Reijke TM, Kurth KH. Prognostic significance and stability of urinary cytokines and albumin following BCG therapy of superficial bladder carcinoma. Urol Res 1993; 21: 461
28. Ratliff TL, Gillen D, Catalona WJ. Requirement of a thymus dependant immune response for BCG-mediated antitumor activity. J Urol 1987; 137: 155-8
29. Bohle A, Gerdes A, Ulmer AJ, Hofstetter AG, Flad HD. Effects of local Bacillus Calmette Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 1990; 144: 53-8
30. El-Demery MIM, Smith G, Ritchie AWS et al. Local immune response after intravesical BCG treatment for carcinoma in situ. Br J Urol 1987; 60: 543-8
31. De Boer EC, De Jong WH, Van der Meijden APM, et al Leucocytes in the urine after intravesical BCG treatment for superficial bladder cancer. Urol Res 1991; 19: 45-50
32. Ratliff TL, Ritchey JK, Yuan JJJ, Andriole GL, Catalona W. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 1993; 150: 1018-23
33. Prescott S, James K, Busutil A, Hargreave TB, Chisholm GD, Smyth J.F. HLD-DR expression by high grade superficial bladder cancer treated with BCG. Br J Urol 1989; 63: 264-9
34. Sprent J, Webb SR. Function and specificity of T cell subsets in the mouse. Adv Immunol 1987; 41: 39-133
35. Lattime EC, Cornelia LG, McCue PA. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. Cancer Res 1992; 52: 4286-90
36. Jackson AM, Prescott S, Hawkyard SJ, James K, Chisholm G. The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical Evans BCG therapy. Cancer Immunol Immunother 1993; 36: 25-30
37. Kamijo R, Le J, Shapiro D et al. Mice that lack the interferon-g receptor have profondly altered responses to infection with bacillus Calmette-Guérin and subsequent challenge with lipopolysaccharide. J Exp Med 1993; 178: 1435-40
38. Thanhauser A, Bohle A, Flad HD, Ernst M, Mattern T, Ulmer AJ. Induction of bacillus Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro. Cancer Immunol Immunother 1993; 37: 105-11
39. Jerome KR, Barnd DL, Bendt KM et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991; 51: 2908-16
40. Bakker ABH, Schreurs WJ, De Boer AJ et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994; 179: 1005-9
41. Boon T, Coulie P, Marchand M, Weynants P, Wölfel T, Brichard V. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. In DeVita VT, Hellman S, Rosenberg SA eds, Important Advances in Oncology. Philadelphia: Lippincott Company, 1994: 53-69